Arrayed CRISPR Screening Market Presents Lucrative Opportunities Through 2026-2030: Total Revenue to Grow by $1.64 Billion at 17.7% CAGR

Industry poised for growth, driven by advancements in precision drug discovery, rising gene therapy investments, and personalized medicine adoption

Dublin, April 20, 2026 (GLOBE NEWSWIRE) -- The "Arrayed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The CRISPR screening market is experiencing significant growth and is forecasted to expand from $1.52 billion in 2025 to $1.79 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.5%. This expansion is attributed to the progress in functional genomics research, the availability of CRISPR editing reagents, academic screening programs, and increased use of cell-based assays.

The market is projected to reach $3.43 billion by 2030, with a CAGR of 17.7%, driven by the demand for precision drug discovery, gene therapy research investments, and bioinformatics-driven screening. Key trends include the focus on targeted gene validation screens and high-throughput arrayed CRISPR assays.

Personalized medicine, which tailors treatments based on genetic and lifestyle factors, is a major driver of the CRISPR screening market's growth. This approach enables customized treatments for better outcomes, and the rise in adoption is fueled by advancements in genomics and molecular diagnostics. As an example, the FDA approved 16 new personalized treatments for rare diseases in 2023, a substantial increase from 2022. The increasing focus on personalized medicine is thus supporting the CRISPR screening market's expansion.

The prevalence of genetic diseases, linked to factors such as advanced parental age, is also propelling the CRISPR screening market forward. This method aids in genetic disease research by identifying disease-causing genes, facilitating the creation of targeted therapies. For instance, the number of registered cystic fibrosis patients increased from 11,148 in 2022 to 11,318 in 2023, underscoring a growing demand for genetic disease solutions.

Strategic partnerships are central to enhancing the precision of CRISPR screening. Noteworthy collaborations include AstraZeneca's partnership with the Medical Research Council and the Milner Therapeutics Institute, leading to the creation of the Functional Genomics Screening Laboratory. This initiative leverages high-throughput automation and collaboration to drive drug discovery, especially in chronic conditions.

Major industry players include Thermo Fisher Scientific , Merck KGaA KGaA, GE HealthCare Technologies Inc, and several others, all striving to enhance CRISPR screening services.

Reasons to Purchase:

• Acquire a global perspective with coverage across 16 geographies.
• Evaluate the influence of macro factors such as geopolitical conflicts, trade policies, inflation, and regulatory modifications.
• Formulate regional and country-specific strategies based on comprehensive local data and analysis.
• Identify growth segments optimal for investment.
• Leverage forecast data to achieve a competitive advantage.
• Understand client segments through detailed end-user analysis.
• Benchmark performance against competitors considering market share, innovation, and brand strength.
• Analyze the Total Addressable Market (TAM) and attractiveness scoring for market potential.
• Empower internal and external presentations with high-quality, reliable data and analysis.
• Receive the latest data updates with an Excel dashboard for efficient information extraction and analysis.

Markets Covered:

• By Product Type: CRISPR Libraries, Reagents, Instruments, Software AG , and Services.
• By Application: Functional Genomics, Drug Discovery, Disease Modeling, Gene Validation.
• By End User: Pharmaceutical Companies, Research Institutes, Contract Research Organizations.

Comprehensive Geographical Analysis Includes: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain, and more.

Time Series: Covers five years of historical data and forecasts for ten years.

Data Segmentation: Offers country, regional historic, and forecast data, as well as competitor market shares.

Key Attributes

The companies featured in this Arrayed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening market report include:

• Thermo Fisher Scientific .
• Merck KGaA KGaA
• GE HealthCare Technologies Inc.
• Applied Biological Materials Inc.
• Agilent Technologies .
• Charles River Laboratories International Inc.
• Integrated DNA Technologies Inc.
• GenScript Biotech Corporation
• Synthego Holdings LLC
• Santa Cruz Biotechnology Inc.
• Creative Biolabs Inc.
• VectorBuilder Inc.
• Admera Health LLC
• Addgene Inc.
• Ncardia
• BioCat GmbH
• Cellecta Inc.
• GeneCopoeia Inc.
• Creative Biogene Inc.
• Aelian Biotechnology

For more information about this report visit https://www.researchandmarkets.com/r/vcm7ls

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Arrayed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening Market

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900